EASTWOOD, Australia,
Jan. 14, 2022 /PRNewswire/ --
Bionomics Limited (Nasdaq: BNOX, ASX: BNO), a clinical-stage
biopharmaceutical developing novel, allosteric ion channel
modulators designed to transform the lives of patients suffering
from serious central nervous system disorders with high unmet
medical need, will ring the Nasdaq Closing Bell remotely from
around the globe.
Dr Errol De Souza, Executive
Chairman, will ring the Closing Bell alongside the Company's team
in a virtual bell ringing ceremony.
When:
FRIDAY, JANUARY 14,
2021 – 3:45 p.m. to 4:00 p.m. ET
Webcast:
A live stream of the Nasdaq Closing Bell will be available at:
https://www.nasdaq.com/marketsite/bell-ringing-ceremony
Social Media:
For multimedia features such as
exclusive content, photo postings, status updates and video of bell
ceremonies, please visit our Facebook page:
http://www.facebook.com/nasdaq.
For photos from ceremonies and events, please visit our
Instagram page: http://instagram.com/nasdaq
Photos:
To obtain a hi-resolution photograph of the
Market Close, please go to
https://www.nasdaq.com/marketsite/bell-ringing-ceremony and
click on the market close of your choice.
FOR FURTHER INFORMATION PLEASE CONTACT:
|
General:
Ms Suzanne
Irwin
Company
Secretary
+61 8 8150
7400
CoSec@bionomics.com.au
|
Investor
Relations:
Mr. Connor
Bernstein
Vice President,
Strategy and Corporate Development
+1 (831) 246
3642
cbernstein@bionomics.com.au
|
About Bionomics Limited:
Bionomics (Nasdaq: BNOX,
ASX:BNO) is a clinical-stage biopharmaceutical developing novel,
allosteric ion channel modulators designed to transform the lives
of patients suffering from serious central nervous system disorders
with high unmet medical need. Bionomics is advancing its lead
product candidate, BNC210, an oral, proprietary, selective negative
allosteric modulator of the α7 nicotinic acetylcholine receptor,
for the acute treatment of Social Anxiety Disorder and chronic
treatment of Post-Traumatic Stress Disorder. Beyond BNC210,
Bionomics has a strategic partnership with Merck & Co., Inc.
(known as MSD outside the United
States and Canada) with two
drugs in early-stage clinical trials for the treatment of cognitive
deficits in Alzheimer's disease and other central nervous system
conditions. To learn more about the company, technology
solutions and career opportunities, visit us on LinkedIn, on
Twitter @Bionomics1, or at www.bionomics.com.au.
About Nasdaq:
Nasdaq (Nasdaq: NDAQ) is a global
technology company serving the capital markets and other
industries. Our diverse offering of data, analytics, software and
services enables clients to optimize and execute their business
vision with confidence. To learn more about the company, technology
solutions and career opportunities, visit us on LinkedIn, on
Twitter @Nasdaq, or at www.nasdaq.com.
View original
content:https://www.prnewswire.com/news-releases/bionomics-limited-nasdaq-bnox-asx-bno-to-ring-the-nasdaq-stock-market-closing-bell-on-friday-january-14-2022-301461190.html
SOURCE Bionomics Limited